ArticleDrug metabolism and disposition: the biological fate of chemicals2025
Visualization of CYP3A4 expression at both mRNA and protein levels simultaneously at single cell resolution in various conditions using RNAscope combined with immunofluorescence.
Article in Drug metabolism and disposition: the biological fate of chemicals, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Precise characterization of drug-metabolizing enzyme expression, such as CYP3A4, at the single-cell resolution is essential for understanding hepatic functional heterogeneity and its impact on xenobiotic clearance. In this study, we employed RNAscope in situ hybridization combined with immunofluorescence to simultaneously visualize CYP3A4 mRNA and protein expression in individual cells under diverse experimental conditions. Using differentiated HepaRG cells, we identified distinct CYP3A4-positive and CYP3A4-negative subpopulations in metabolic zonation. Nonconfluent HepG2 and Huh7 cells showed nearly undetectable CYP3A4 mRNA and protein signals. Five distinct CYP3A4 expression patterns were identified in differentiated HepaRG cells, capturing various stages of mRNA and protein production and reflecting the stepwise progression of gene expression from transcription to translation at single-cell resolution. CYP3A4-positive cells showed dynamic changes during growth and differentiation stages in HepaRG cells. Metabolic stressors, such as free fatty acids, significantly downregulated CYP3A4 expression in steatotic HepaRG cells, identified by lipid droplet morphology. Hepatotoxicity inducer acetaminophen resulted in significant cell death and downregulated CYP3A4 expression, sensitive only to CYP3A4-positive cells but not to CYP3A4-negative cells. Exposure of rifampicin to differentiated HepaRG cells induced CYP3A4 at both transcriptional and translational levels, but only in CYP3A4-positive cells, not CYP3A4-negative cells. In conclusion, the combined RNAscope-immunofluorescence approach enabled analysis of cell type-specific and condition-dependent regulation of CYP3A4 at single-cell resolution, revealing transcription-translation discordance and metabolic zonation-like effects. This approach provides a powerful tool for studying hepatic drug metabolism and toxicity in heterogeneous liver models. SIGNIFICANCE STATEMENT: This study introduces a powerful dual-modality imaging approach that enables simultaneous visualization of CYP3A4 mRNA and protein at single-cell resolution with heterogeneous hepatic cultures. By integrating RNAscope with immunofluorescence, this study uncovers how metabolic stressors and drug inducers differentially modulate CYP3A4 expression across distinct liver cell subtypes. This platform enhances the ability to study cell type-specific drug metabolism, offering critical insights into hepatic functional heterogeneity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.